Michael Untch

18PUBLICATIONS
182CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Apr 20, 2026
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.

|Jan 21, 2026
Marking Techniques for Target Lymph Nodes in Node-Positive Breast Cancer Treated With Neoadjuvant Therapy in the AXSANA/EUBREAST-03/AGO-B-053 Study.

Maggie Banys-Paluchowski, Steffi Hartmann, Jana de Boniface

|Sep 13, 2025
Ribosomal RNA Degradation (RNA Disruption) in Tumour Cells: Mechanistic Insights and Potential Clinical Utility.

Amadeo M Parissenti, Sanaa Noubir, Laura B Pritzker

|Apr 10, 2025
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Feb 28, 2025
Health-Related Quality of Life in Patients with HR+/HER2- Early Breast Cancer Treated with Ribociclib Plus a Nonsteroidal Aromatase Inhibitor: Results from the NATALEE Trial.

Peter A Fasching, Dennis Slamon, Zbigniew Nowecki

|Feb 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.

Peter A Fasching, Sabine Schmatloch, Jan Hauke

Pageof 3

Frequent Collaborators

14 joint publications

Sibylle Loibl

13 joint publications

Carsten Denkert

11 joint publications

Valentina Nekljudova

11 joint publications

Peter Fasching